Your browser doesn't support javascript.
loading
Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics".
Bovijn, Jonas; Krebs, Kristi; Chen, Chia-Yen; Boxall, Ruth; Censin, Jenny C; Ferreira, Teresa; Pulit, Sara L; Glastonbury, Craig A; Laber, Samantha; Millwood, Iona Y; Lin, Kuang; Li, Liming; Chen, Zhengming; Milani, Lili; Smith, George Davey; Walters, Robin G; Mägi, Reedik; Neale, Benjamin M; Lindgren, Cecilia M; Holmes, Michael V.
Afiliação
  • Bovijn J; Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7FZ, UK.
  • Krebs K; Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Chen CY; Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu 51010, Estonia.
  • Boxall R; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Censin JC; Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Ferreira T; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Pulit SL; Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
  • Glastonbury CA; Medical Research Council Population Health Research Unit (MRC PHRU), Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
  • Laber S; Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7FZ, UK.
  • Millwood IY; Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Lin K; Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7FZ, UK.
  • Li L; Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7FZ, UK.
  • Chen Z; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA.
  • Milani L; Department of Genetics, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands.
  • Smith GD; Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7FZ, UK.
  • Walters RG; Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7FZ, UK.
  • Mägi R; Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Neale BM; Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
  • Lindgren CM; Medical Research Council Population Health Research Unit (MRC PHRU), Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
  • Holmes MV; Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
Sci Transl Med ; 13(622): eabf4530, 2021 12.
Article em En | MEDLINE | ID: mdl-34851696
Triangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article